|
12 Aug 2019 |
RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6)
|
|
10 Aug 2019 |
Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease
|
|
10 Aug 2019 |
Coordination Pharmaceuticals Announces Enrollment of the First Patient in Phase 1 Study of CPI-200 in Patients With Advanced Tumors
|
|
10 Aug 2019 |
Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
|
|
09 Aug 2019 |
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
|
|
08 Aug 2019 |
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
|
|
08 Aug 2019 |
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
|
|
08 Aug 2019 |
Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus
|
|
08 Aug 2019 |
Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
|
08 Aug 2019 |
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
|
|
07 Aug 2019 |
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
|
|
07 Aug 2019 |
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
|
|
07 Aug 2019 |
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
|
|
07 Aug 2019 |
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
|
|
07 Aug 2019 |
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
|
|
07 Aug 2019 |
Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
|
|
07 Aug 2019 |
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
|
|
06 Aug 2019 |
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
|
|
06 Aug 2019 |
Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial
|
|
06 Aug 2019 |
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
|
